Sarah Marktel

Sarah Marktel

Auto-generated profile, based on publicly available information

Sarah Marktel

IRCCS San Raffaele Hospital, Hematology, Milan, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
VFValeria Ferla
Valeria Ferla
EAElena Antonini
Elena Antonini
TPTommaso Perini
Tommaso Perini
FFFrancesca Farina
Francesca Farina
SMSerena Masottini
Serena Masottini
MMMagda Marcatti
Magda Marcatti
Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple myeloma (MM) remains an incurable disease, as a major portion of patients even in complete response eventually relapse, suggesting that residual disease remains. Over the past decade, the treatment landscape of MM has radically changed with the introduction of new effective drugs and the availability of immunotherapy, including targeted antibodies and adoptive cell therapy. Therefore, conventional serological and morphological techniques have become suboptimal for the evaluation of depth of response. Recently, the International Myeloma Working Group (IMWG) introduced the definition of MRD negativity as the absence of clonal Plasma cells (PC) with a minimum sensitivity of <10−5 either by next-generation sequencing (NGS) using the LymphoSIGHT platform (Sequenta/Adaptative) or by next-generation flow cytometry (NGF) using EuroFlow approaches as the reference methods. While the definition of the LymphoSIGHT platform (Sequenta/Adaptive) as the standard method derives from its large use and validation in clinical studies on the prognostic value of NGS-based MRD, other commercially available options exist. Recently, the LymphoTrack assay has been evaluated in MM, demonstrating a sensitivity level of 10−5, hence qualifying as an alternative effective tool for MRD monitoring in MM. Here, we will review state-of-the-art methods for MRD assessment by NGS. We will summarize how MRD testing supports clinical trials as a useful tool in dynamic risk-adapted therapy. Finally, we will also discuss future promise and challenges of NGS-based MRD determination for clinical decision-making. In addition, we will present our real-life single-center experience with the commercially available NGS strategy LymphoTrack-MiSeq. Even with the limitation of a limited number of patients, our results confirm the LymphoTrack-MiSeq platform as a cost-effective, readily available, and standardized workflow with a sensitivity of 10−5. Our real-life data also confirm that achieving MRD negativity is an important prognostic factor in MM.

2 November 2009 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
IFI Frugnoli
I Frugnoli
BCB Cappelli
B Cappelli
RCR Chiesa
R Chiesa
EBE Biral
E Biral
ANA Noè
A Noè
SMS Marktel
S Marktel

29 May 2022 in European Journal of Immunology
Verified
Journal Article
Open access
GMGiulia Milardi
Giulia Milardi
BLBiagio Di Lorenzo
Biagio Di Lorenzo
JGJolanda Gerosa
Jolanda Gerosa
FBFederica Barzaghi
Federica Barzaghi
GMGigliola Di Matteo
Gigliola Di Matteo
GFGeorgia Fousteri
Georgia Fousteri
Common variable immunodeficiency (CVID) is the most frequent primary antibody deficiency whereby follicular helper T (Tfh) cells fail to establish productive responses with B cells in germinal centers. Here, we analyzed the frequency, phenotype, transcriptome, and function of circulating Tfh (cTfh) cells in CVID patients displaying autoimmunity as an additional phenotype. A group of patients showed a high frequency of cTfh1 cells and a prominent expression of PD‐1 and ICOS as well as a cTfh mRNA signature consistent with highly activated, but exhausted, senescent, and apoptotic cells. Plasmatic CXCL13 levels were elevated in this group and positively correlated with cTfh1 cell frequency and PD‐1 levels. Monoallelic variants in RTEL1, a telomere length‐ and DNA repair‐related gene, were identified in four patients belonging to this group. Their blood lymphocytes showed shortened telomeres, while their cTfh were more prone to apoptosis. These data point toward a novel pathogenetic mechanism in CVID, whereby alterations in DNA repair and telomere elongation might predispose to antibody deficiency. A Th1, highly activated but exhausted and apoptotic cTfh phenotype was associated with this form of CVID.

1 July 2010 in Journal of Medical Microbiology
Verified
Journal Article
Closed access
MFMarco Fossati
Marco Fossati
BCBarbara Cappelli
Barbara Cappelli
EBErika Biral
Erika Biral
RCRobert Chiesa
Robert Chiesa
ABAlessandra Biffi
Alessandra Biffi
SMSarah Marktel
Sarah Marktel
Recently vancomycin-resistant and sporadically linezolid-resistant Enterococcus species have been described in adults. We report what we believe to be the first case of a child with prolonged bone marrow aplasia following haematopoietic stem cell transplantation developing a fatal sepsis caused by Enterococcus faecium resistant to glycopeptides and linezolid.

20 November 2009 in Blood
Verified
Journal Article
Open access
JPJacopo Peccatori
Jacopo Peccatori
DCDaniela Clerici
Daniela Clerici
CMCarlo Messina
Carlo Messina
AFAlessandra Forcina
Alessandra Forcina
ABAttilio Bondanza
Attilio Bondanza
FCFabio Ciceri
Fabio Ciceri
Abstract 666

8 August 2023 in HemaSphere
Verified
Journal Article
Open access
TPTommaso Perini
Tommaso Perini
CLCarmine Liberatore
Carmine Liberatore
GVGirlando Virginia
Girlando Virginia
CPCecilia Passeri
Cecilia Passeri
VFValeria Ferla
Valeria Ferla
MMMagda Marcatti
Magda Marcatti